临床试验/IRCT20210519051345N14

IRCT20210519051345N14尚未招募未知

Bioequivalence study of Apprepitant 125 mg capsule manufactured by Avicenna Co. compared with innovator product

Tabriz University of Medical Sciences0 个研究点目标入组 24 人开始时间: 待定最近更新: 2022年8月29日

试验速览

阶段: 未知
状态: 尚未招募
发起方: Tabriz University of Medical Sciences
入组人数: 24

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 years 至 59 years（—）
性别: All

入选标准

•General Health (in terms of Liver, Heart and Kidney)
•Age (18-59 years old)

排除标准

•History of cardiovascular disease, liver and kidney disease,
•Alcohol and drug addiction,
•History of drug allergy

研究者

发起方

Tabriz University of Medical Sciences

相似试验

Bioequivalence study of Aprepitant 125 mg capsule in 24 healthy male under fasting conditionsBioequivalence investigation of the generic Actover.Aprepitant 125 mg capsule with brand EMEND® Merk capsule..

IRCT20180620040164N10ACtover Pharmaceutical Co.26

Investigating the in vivo bioequivalence of Apixaban tabletIn the present study, the products will be administered to healthy volunteers..

IRCT20220211053992N10Tabriz University of Medical Sciences24

Bioequivalence of Apixaba

IRCT20210201050197N4Shahid Beheshti University of Medical Sciences24

Bioequivalence study of Abirateron 500mg tablet

IRCT20200105046010N87Tabriz University of Medical Sciences24

Comparative in vivo evaluation of 2 ?Apixaban 5 mg Tablet formulations.

IRCT20180620040164N37Actover Pharmaceutical Co.24